⚡ MARKET RECAP → Stocks made a comeback from earlier losses on Monday after President Donald Trump said the war with Iran could be reaching its end.

💊 NOVO DROPS FIGHT WITH HIMS → Novo Nordisk has ended legal proceedings against Hims & Hers over compounded GLP-1 weight-loss drugs, easing immediate legal pressure on the telehealth company while leaving the broader regulatory battle over compounded alternatives unresolved.

🎲 WAR BETS SURGE ON PREDICTION MARKETS → Wagers on platforms like Kalshi and Polymarket tied to potential Iran conflict scenarios are exploding in volume, sparking debate over whether prediction markets offer useful forecasting signals — or dangerously turn geopolitical crises into tradable speculation.

Was this email forwarded to you? Sign up for free here.

For the week beginning March 9, 2026

💊 Novo Nordisk is backing off its legal battle with Hims & Hers over compounded weight-loss drugs. The pharmaceutical giant ended proceedings tied to allegations that the telehealth company was improperly selling compounded versions of popular GLP-1 medications like Wegovy. The move removes a major legal overhang that had weighed on Hims & Hers’ stock and business model.

⚖️ The dispute centered on compounded alternatives. Drugmakers including Novo Nordisk have argued that compounding pharmacies and telehealth platforms exploit supply shortages of branded GLP-1 drugs to sell similar formulations outside the traditional pharmaceutical distribution system. Critics say this undermines intellectual property protections and safety oversight, while telehealth firms argue it expands patient access amid shortages.

📊 Investors see regulatory risk easing — for now. With Novo stepping back, Hims & Hers (HIMS) gains breathing room to continue offering compounded GLP-1 treatments while branded supply remains constrained. But the broader fight between drugmakers, compounding pharmacies and telehealth platforms over weight-loss medications is far from settled as demand continues to surge.

🎲 Millions are pouring into prediction markets tied to a potential Iran war. Platforms like Kalshi and Polymarket have seen a surge in wagers on geopolitical outcomes — including whether the U.S. or Israel will strike Iran, leadership changes in Tehran, and other conflict-related scenarios. Prediction markets let users trade contracts priced between $0 and $1 that represent the perceived probability of an event occurring.

⚖️ The boom is raising legal and ethical alarms. Lawmakers and analysts warn that allowing bets on military action could create incentives for insider trading or the misuse of classified information. Some traders have already profited heavily from well-timed wagers tied to geopolitical developments, fueling calls in Congress to regulate or ban such markets for national-security reasons.

📊 For investors, these markets are both signal and spectacle. Advocates say prediction markets aggregate real-time information better than polls or analyst forecasts, while critics argue they blur the line between financial forecasting and gambling on war. Either way, their rising volume shows how geopolitics is increasingly being traded like an asset class.

Oil prices fall below $100 per barrel as G7 energy ministers to meet on stockpile release (CNBC)

Anthropic sues Trump administration over Pentagon blacklist (CNBC)

Morgan Stanley downgrades this investment bank, cites ongoing legal and credit risks (CNBC)

_{^{Investment advisory services provided by ML Wealth LLC. Investment Accounts Are Not FDIC Insured • No Bank Guarantee • Investments May Lose Value. For important information and disclosures relating to the MoneyLion Investment Account, see Investment FAQs, Form ADV Brochure, and moneylion.com/investing. Funded managed investing accounts are subject to a monthly account fee of $1 (for accounts valued up to $5,000), $3 (for accounts valued over $5,000, and up to $25,000), or $5 (for accounts valued over $25,000).}}

<sub><sup>This advertising email was sent to you because you have a MoneyLion account. If you would like to unsubscribe, please do so using this link. We respect your right to privacy. Please do not reply to this email with sensitive information, such as an account number, Social Security number, date of birth, bank account information, PIN, password, or Online ID. The security and confidentiality of your personal information is important to us. If you have any questions or want to read more, please visit our Help Center.

MoneyLion and Pathward do not provide, nor do they guarantee, any third-party product, service, information, or recommendation. The third parties providing these products or services are solely responsible for them, as well as all other content on their websites. MoneyLion is not liable for any third party’s failure with regard to those advertised products, services, and benefits. These advertised products and services may not be FDIC insured or bank-guaranteed, and may be subject to a different privacy policy than MoneyLion’s. You should check individual offers, products, and services to become familiar with any applicable restrictions or conditions that may apply. MoneyLion may receive compensation from third parties for referring you to the third party, their products or to their website.

The influencer, creator and other content provided in the MoneyLion App (“Content”) is for informational and entertainment purposes only and should not be construed as legal, tax, investment, financial, or other advice. All Content is intended to be of a general nature, does not address the circumstances of any particular individual or entity, and may not constitute a comprehensive or complete statement of the matters discussed. MoneyLion is not a fiduciary by virtue of any person’s use of or reliance on the Content. You should consult an appropriate professional if you require any legal, tax, investment, financial or other advice. Terms and Conditions for our subscriber referral can be found here.</sup></sub>